Amended Statement of Beneficial Ownership (sc 13d/a)
03 Mars 2023 - 4:08PM
Edgar (US Regulatory)
Page 1 of 10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*
CinCor Pharma,
Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
17240Y109
(CUSIP Number)
Armance Bordes
Sofinnova Partners
7-11 blvd Haussmann
75009 Paris
France
+33 1 53 05 41 00
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
February 24, 2023
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement
on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. o
Note: Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are
to be sent.
* The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
CUSIP No. 17240Y109 |
Page 2 of 10 |
1. |
Name of Reporting Persons
Sofinnova Capital IX FPCI (“SC IX”) |
2. |
Check
the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x |
3. |
SEC USE ONLY
|
4. |
Source of Funds (see instructions)
WC |
5. |
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
¨ |
6. |
Citizenship or Place of
Organization
France |
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole
Voting Power
0 |
8. |
Shared
Voting Power
0 |
9. |
Sole
Dispositive Power
0 |
|
10. |
Shared
Dispositive Power
0 |
11. |
Aggregate Amount Beneficially
Owned by Each Reporting Person
0
|
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions) ¨ |
13. |
Percent of Class Represented
by Amount in Row 11
0 |
14. |
Type of Reporting Person
(see instructions)
00 |
|
|
|
|
|
CUSIP No. 17240Y109 |
Page 3 of 10 |
1. |
Name of Reporting Persons
Sofinnova Partners SAS (“SP SAS”) |
2. |
Check
the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x |
3. |
SEC USE ONLY
|
4. |
Source of Funds (see instructions)
00 |
5. |
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
¨ |
6. |
Citizenship or Place of
Organization
France |
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole
Voting Power
0 |
8. |
Shared
Voting Power
0 |
9. |
Sole
Dispositive Power
0 |
|
10. |
Shared
Dispositive Power
0 |
11. |
Aggregate Amount Beneficially
Owned by Each Reporting Person
0
|
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions) ¨ |
13. |
Percent of Class Represented
by Amount in Row 11
0 |
14. |
Type of Reporting Person
(see instructions)
00 |
|
|
|
|
|
CUSIP No. 17240Y109 |
Page 4 of 10 |
1. |
Name of Reporting Persons
Antoine Papiernik (“Papiernik”) |
2. |
Check
the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x |
3. |
SEC USE ONLY
|
4. |
Source of Funds (see instructions)
00 |
5. |
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
¨ |
6. |
Citizenship or Place of
Organization
French Citizen |
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole
Voting Power
0 |
8. |
Shared
Voting Power
0 |
9. |
Sole
Dispositive Power
0 |
|
10. |
Shared
Dispositive Power
0 |
11. |
Aggregate Amount Beneficially
Owned by Each Reporting Person
0
|
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions) ¨ |
13. |
Percent of Class Represented
by Amount in Row 11
0 |
14. |
Type of Reporting Person
(see instructions)
IN |
|
|
|
|
|
CUSIP No. 17240Y109 |
Page 5 of 10 |
1. |
Name of Reporting Persons
Henrijette Richter (“Richter”) |
2. |
Check
the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x |
3. |
SEC USE ONLY
|
4. |
Source of Funds (see instructions)
00 |
5. |
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
¨ |
6. |
Citizenship or Place of
Organization
Danish Citizen |
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole
Voting Power
0 |
8. |
Shared
Voting Power
0 |
9. |
Sole
Dispositive Power
0 |
|
10. |
Shared
Dispositive Power
0 |
11. |
Aggregate Amount Beneficially
Owned by Each Reporting Person
0
|
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions) ¨ |
13. |
Percent of Class Represented
by Amount in Row 11
0 |
14. |
Type of Reporting Person
(see instructions)
IN |
|
|
|
|
|
CUSIP No. 17240Y109 |
Page 6 of 10 |
1. |
Name of Reporting Persons
Monique Saulnier (“Saulnier”) |
2. |
Check
the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x |
3. |
SEC USE ONLY
|
4. |
Source of Funds (see instructions)
00 |
5. |
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
¨ |
6. |
Citizenship or Place of
Organization
French Citizen |
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole
Voting Power
0 |
8. |
Shared
Voting Power
0 |
9. |
Sole
Dispositive Power
0 |
|
10. |
Shared
Dispositive Power
0 |
11. |
Aggregate Amount Beneficially
Owned by Each Reporting Person
0
|
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions) ¨ |
13. |
Percent of Class Represented
by Amount in Row 11
0 |
14. |
Type of Reporting Person
(see instructions)
IN |
|
|
|
|
|
CUSIP No. 17240Y109 |
Page 7 of 10 |
1. |
Name of Reporting Persons
Maina Bhaman (“Bhaman”) |
2. |
Check
the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x |
3. |
SEC USE ONLY
|
4. |
Source of Funds (see instructions)
00 |
5. |
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
¨ |
6. |
Citizenship or Place of
Organization
British Citizen |
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole
Voting Power
0 |
8. |
Shared
Voting Power
0 |
9. |
Sole
Dispositive Power
0 |
|
10. |
Shared
Dispositive Power
0 |
11. |
Aggregate Amount Beneficially
Owned by Each Reporting Person
0
|
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions) ¨ |
13. |
Percent of Class Represented
by Amount in Row 11
0 |
14. |
Type of Reporting Person
(see instructions)
IN |
|
|
|
|
|
CUSIP No. 17240Y109 |
Page 8 of 10 |
1. |
Name of Reporting Persons
Graziano Seghezzi (“Seghezzi”) |
2. |
Check
the Appropriate Box if a Member of a Group (see instructions)
(a)
(b)
|
¨
x |
3. |
SEC USE ONLY
|
4. |
Source of Funds (see instructions)
00 |
5. |
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
¨ |
6. |
Citizenship or Place of
Organization
Italian Citizen |
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7. |
Sole
Voting Power
0 |
8. |
Shared
Voting Power
0 |
9. |
Sole
Dispositive Power
0 |
|
10. |
Shared
Dispositive Power
0 |
11. |
Aggregate Amount Beneficially
Owned by Each Reporting Person
0
|
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions) ¨ |
13. |
Percent of Class Represented
by Amount in Row 11
0 |
14. |
Type of Reporting Person
(see instructions)
IN |
|
|
|
|
|
Page 9 of 10
Amendment No. 1 to Schedule 13D
This Amendment No. 1 amends and supplements that
certain Statement on Schedule 13D filed with the SEC by the Reporting Persons on February 13, 2023 (the “Schedule 13D”). Except
as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D. Capitalized
terms used herein shall have the meanings ascribed to them in the Schedule 13D.
| Item 4. | Purpose of Transaction. |
Item 4 of the Schedule 13D is hereby amended and
supplemented as follows:
On February 24, 2023, pursuant to the Merger Agreement,
Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and
into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the
"Cash Amount"), plus (ii) one contingent value right (each, a "CVR") per Share representing the right to receive a
contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus
one CVR, collectively, the "Offer Price"), in each case, without interest, subject to any applicable withholding taxes. Pursuant
to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger
Agreement) in exchange for the right to receive the Offer Price.
Upon the consummation of the Merger, none of the
Reporting Persons may be deemed to beneficially own any Shares.
| Item 5. | Interest in Securities of the Issuer. |
Item 5 of the Schedule 13D is hereby amended and
restated in its entirety as follows:
| (a)-(c) | See Item 4 above. None of the Reporting Persons may be deemed to beneficially own any Shares. |
| (e) | As of February 24, 2023, each of the Reporting Persons ceased to be the beneficial owner of more than
five percent of the Issuer’s common stock. |
| Item 6. | Interest in Securities of the Issuer. |
Item 6 of the Schedule 13D is hereby amended and
restated in its entirety as follows:
Not applicable.
| Item 7. | Material to Be Filed as Exhibits. |
Page 10 of 10
SIGNATURE
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: March 3, 2023
SOFINNOVA CAPITAL
VI FCPR | |
SOFINNOVA PARTNERS SAS |
By: Sofinnova Partners SAS | |
|
|
|
| |
|
|
By: |
/s/ Monique Saulnier | |
By: |
/s/ Monique Saulnier |
Name: |
Monique Saulnier | |
Name: |
Monique Saulnier |
Title: |
Managing Partner | |
Title: |
Managing Partner |
|
| |
|
|
By: |
/s/ Maina Bhaman | |
By: |
/s/ Monique Saulnier |
Name: |
Maina Bhaman | |
Name: |
Monique Saulnier |
|
| |
|
|
By: |
/s/ Antoine Papiernik | |
By: |
/s/ Henrijette Richter |
Name: |
Antoine Papiernik | |
Name: |
Henrijette Richter |
|
| |
|
|
By: |
/s/ Graziano Seghezzi | |
|
|
Name: |
Graziano Seghezzi | |
|
|
CinCor Pharma (NASDAQ:CINC)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
CinCor Pharma (NASDAQ:CINC)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025